Skip to main content

Table 1 Patients’ clinical and biological characteristics

From: Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients

Initial characteristics
Tumor biology group, n (%)
  HER2+ HR+ 58 (23.2)
  HER2+ HR- 61 (24.4)
  HER2- HR+ 64 (25.6)
  Triple negative 67 (26.8)
 ER status, n (%)
  Negative 128 (51.2)
  Positive 122 (48.8)
 PR status, n (%)
  Negative 186 (74.7)
  Positive 63 (25.3)
  Missing 1
 HER2 status, n (%)
  Negative 131 (52.4)
  Positive 119 (47.6)
 Histological subtype, n (%)
  Ductal carcinoma 203 (82.9)
  Other subtypesa 42 (17.1)
  Missing 5
 Histological grade (SBR), n (%)
  1 or 2 103 (45.8)
  3 122 (54.2)
  Missing 25
 Inflammatory BC, n (%)
  No 216 (90.8)
  Yes 22 (9.2)
  Missing 12
 Metastatic status at BC diagnosis, n (%)
  M0 174 (71.3)
  M1 70 (28.7)
  Mx 6
Patients’ characteristics at the time of the serum sample
 Median age in years (range) 58.4 (26.4–87.2)
 Age group, n (%)
  < 50 77 (30.8)
  50 to 70 132 (52.8)
  > 70 41 (16.4)
 Median number of lines of CT (range) 1 (0–9)
 Number of lines of CT, n (%)
  0 line 61 (24.4)
  1 or 2 line(s) 113 (45.2)
  > 2 lines 76 (30.4)
 Previous anti-HER2 treatment, n (%)
  No 149 (59.6)
  Yes 101 (40.4)
 Brain metastases, n (%) 88 (35.2)
 Liver metastases, n (%) 152 (60.8)
 Bone metastases, n (%) 142 (56.8)
 Lung metastases, n (%) 125 (50.0)
 Lymph node metastases, n (%) 134 (53.6)
 Subcutaneous metastases, n (%) 43 (17.2)
 Pleural metastases, n (%) 55 (22.0)
 Metastases of other sites, n (%) 109 (43.6)
 ECOG status, n (%)
  0 70 (30.2)
  1 106 (45.7)
  2 34 (14.7)
  3 22 (9.5)
  Missing 18
 Anemia, n (%)
  No 38 (25.9)
  Yes 109 (74.1)
  Missing 103
 Leucopenia, n (%)
  No 118 (82.5)
  Yes 25 (17.5)
  Missing 107
 Neutropenia, n (%)
  No 129 (89.0)
  Yes 16 (11.0)
  Missing 105
 Lymphopenia, n (%)
  No 82 (59.4)
  Yes 56 (40.6)
  Missing 112
 Thrombopenia, n (%)
  No 128 (88.3)
  Yes 17 (11.7)
  Missing 105
 Elevated LDH, n (%)
  No 51 (56.7)
  Yes 39 (43.3)
  Missing 160
 Elevated serum CEA, n (%)
  No 154 (66.4)
  Yes 78 (33.6)
  Missing 18
 Elevated serum CA 15-3, n (%)
  No 92 (39.7)
  Yes 140 (60.3)
  Missing 18
 Elevated serum HER2 ECD (cut-off 15 ng/mL)
  No 107 (42.8)
  Yes 143 (57.2)
  Missing 0
 Elevated serum HER2 ECD (cut-off 30 ng/mL)
  No 187 (74.8)
  Yes 63 (25.2)
  Missing 0
 Elevated serum NSE (cut-off 12.5 μg/L)
  No 76 (30.5)
  Yes 173 (69.5)
  Missing 1
 Elevated serum MMP9 (cut-off 50 ng/mL)
  No 6 (2.4)
  Yes 244 (97.6)
  Missing 0
 Elevated serum S100ß (cut-off 0.12 μg/L)
  No 224 (92.2)
  Yes 19 (7.8)
  Missing 7
 Elevated serum S100ß (cut-off 0.072 μg/L)
  No 183 (75.3)
  Yes 60 (24.7)
  Missing 7
 Low protein level, n (%)
  No 32 (74.4)
  Yes 11 (25.6)
  Missing 119
 Low albumin level, n (%)
  No 135 (85.4)
  Yes 23 (14.6)
  Missing 92
Follow-up
 Status as last follow-up, n (%)
  Alive 77 (30.8)
  Dead 173 (69.2)
 Cause of death, n (%) (174 deceased)
  Oncological disease 153 (87.9)
  Non-oncological 4 (2.3)
  Toxic 4 (2.3)
  Unknown 13 (7.5)
  1. Abbreviations: ER estrogen-receptors, PR progesterone-receptors, SBR Scarf, Bloom and Richardson, BC breast cancer, CT chemotherapy, LDH Lactate Deshydrogenase, CEA Carcinoembryonic Antigen, CA 15-3 Cancer Antigen 15-3, HER2-ECD HER2 extra-cellular domain, NSE Neuron Specific Enolase, MMP-9 Matrix Metalloproteinase 9
  2. a lobular carcinoma (n = 21), mucinous carcinoma (n = 1), papillary carcinoma (n = 3), medullary carcinoma (n = 1), mixed ductal and lobular carcinoma (n = 12), other histological subtypes (n = 4)